AstraZeneca Plc to increase Dividend by 7% for 2024

AZN

AstraZeneca plc (LON:AZN) has announced that the Board intends to increase the annualised dividend for 2024 by $0.20 to $3.10 per share, underlining the company’s confidence in its performance and cash generation. This takes into account other capital allocation priorities as well as previously announced acquisitions and business development.

Michel Demaré, Chair, said: “The Board is delighted to announce a 7% increase to the dividend, taking it to $3.10 per share. This uplift is in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca’s investment proposition for shareholders.”

No changes are planned to the Company’s normal dividend payment timetable, which is:

·    First interim dividend – announced with half-year results and paid in September.

·    Second interim dividend – announced with full-year results and paid in March.

The Board also reaffirms its commitment to AstraZeneca’s progressive dividend policy.

Share on:

Latest Company News

AstraZeneca invests $2bn in Summit to accelerate ivonescimab development

AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in combination with ADCs. The companies will also collaborate on trials combining ivonescimab with Sone-Ve across gastrointestinal cancers.

AstraZeneca’s Trixeo Aerosphere approved in EU for asthma

The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose asthma is inadequately controlled with medium-dose ICS/LABA therapy.

AstraZeneca’s Klygefa recommended for EU approval in generalised myasthenia gravis

The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised myasthenia gravis, based on Phase III PREVAIL trial results.

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.

    Search